Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8030467 | 0.95 | — | — | |
| Bromide SCHEMBL10535041 | 0.73 | HRH4 (0.47) | — | |
| Bromide SCHEMBL7434195 | 0.70 | — | — | |
| Bromide SCHEMBL10831404 | 0.70 | — | — | |
| Guanidine SCHEMBL2340600 | 0.68 | — | — | |
| SCHEMBL2769932 | 0.67 | — | — | |
| SCHEMBL1419564 | 0.67 | — | — | |
| SCHEMBL676868 | 0.67 | — | — | |
| SCHEMBL3152629 | 0.64 | — | — | |
| SCHEMBL3152626 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0774514-B1 | A method for quantitatively determining creatine kinase and a reagent therefor | KYOWA MEDEX CO LTD (JP) | 2000-03-08 | — | — | EP | claimed |
| JP-10327895-A | — | — | None | — | — | JP | disclosed |
| US-5662905-A | PROTECTION AGAINST PSEUDOMONAS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-09-02 | — | — | US | disclosed |
| US-5628996-A | Method for inhibiting the viability of Pseudomonas aeruginosa with cross-reactive and cross-protective monoclonal antibodies | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-05-13 | — | — | US | disclosed |
| US-5378812-A | Human antibodies which specifically bind to lipopolysaccharide determinants of some pseudomonas serotypes and inhibit these bacteria, for prevention and treatment of infections | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-03 | — | — | US | disclosed |
| US-4834976-A | Monoclonal antibodies to pseudomonas aeruginosa flagella | GENETIC SYSTEMS CORPORATION (US) | 1989-05-30 | — | — | US | disclosed |